Effects of omecamtiv mecarbil in heart failure with reduced ejection fraction according to blood pressure: the GALACTIC-HF trial.

MLA

Metra, Marco, et al. “Effects of Omecamtiv Mecarbil in Heart Failure with Reduced Ejection Fraction According to Blood Pressure: The GALACTIC-HF Trial.” European Heart Journal, vol. 43, no. 48, Dec. 2022, pp. 5006–16. EBSCOhost, https://doi.org/10.1093/eurheartj/ehac293.

APA

Metra, M., Pagnesi, M., Claggett, B. L., Díaz, R., Felker, G. M., McMurray, J. J. V., Solomon, S. D., Bonderman, D., Fang, J. C., Fonseca, C., Goncalvesova, E., Howlett, J. G., Li, J., O’Meara, E., Miao, Z. M., Abbasi, S. A., Heitner, S. B., Kupfer, S., Malik, F. I., & Teerlink, J. R. (2022). Effects of omecamtiv mecarbil in heart failure with reduced ejection fraction according to blood pressure: the GALACTIC-HF trial. European Heart Journal, 43(48), 5006–5016. https://doi.org/10.1093/eurheartj/ehac293

Chicago

Metra, Marco, Matteo Pagnesi, Brian L Claggett, Rafael Díaz, G Michael Felker, John J V McMurray, Scott D Solomon, et al. 2022. “Effects of Omecamtiv Mecarbil in Heart Failure with Reduced Ejection Fraction According to Blood Pressure: The GALACTIC-HF Trial.” European Heart Journal 43 (48): 5006–16. doi:10.1093/eurheartj/ehac293.